Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

Next Previous
Trial Profile

I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Aviptadil (Primary) ; Celecoxib (Primary) ; Cenicriviroc (Primary) ; Dornase alfa (Primary) ; Famotidine (Primary) ; Icatibant (Primary) ; Narsoplimab (Primary) ; Razuprotafib (Primary) ; Remdesivir (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Acronyms I-SPY COVID; I-SPY COVID

    • Most Recent Events

    • 12 Mar 2024 Planned End Date changed from 1 Nov 2024 to 31 Jul 2030.
    • 12 Mar 2024 Planned primary completion date changed from 24 Jul 2023 to 31 Jul 2028.
    • 05 Feb 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top